Prognostic Value of p53 for High Risk Superficial Bladder Cancer With Long-Term Followup

Journal of Urology

Volumn 177, Issue 1, 2007, Pages 80-83

  Moonen, P M J ^a   van Balken Ory, B ^a   Kiemeney, L A L M ^a   Schalken, J A ^a   Witjes, J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

bladder; bladder neoplasms; genes, p53; prognosis

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; AUTOANALYSIS; BLADDER CANCER; BLADDER IRRIGATION; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SAMPLE; STATISTICAL SIGNIFICANCE; SUPERFICIAL CANCER; TUMOR SUPPRESSOR GENE; WILD TYPE;

DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 33845304992     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.08.110     Document Type: Article

References (20)

1. Kiemeney L.A., Witjes J.A., Heijbroek R.P., Verbeek A.L., and Debruyne F.M. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 150 (1993) 60
2. Fitzpatrick J.M., West A.B., Butler M.R., Lane V., and O'Flynn J.D. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 135 (1986) 920
3. Herr H.W. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 80 (1997) 762
4. Cheng L., Cheville J.C., Neumann R.M., Leibovich B.C., Egan K.S., Spotts B.E., et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 85 (1999) 2469
5. Schrier B.P., Hollander M.P., van Rhijn B.W., Kiemeney L.A., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45 (2004) 292
6. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323
7. Esrig D., Spruck III C.H., Nichols P.W., Chaiwun B., Steven K., Groshen S., et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143 (1993) 1389
8. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49
9. th (2002), Springer-Verlag, Heidelberg 335-340 part IX
10. Histological Typing of Urinary Bladder Tumours. International Histological Classification of Tumours, No. 10 (1973), World Health Organization, Geneva, Switzerland
11. Sarkis A.S., Dalbagni G., Cordon-Cardo C., Melamed J., Zhang Z.F., Sheinfeld J., et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 152 (1994) 388
12. Schmitz-Drager B.J., van Roeyen C.R., Grimm M.O., Gerharz C.D., Decken K., Schulz W.A., et al. P53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol 12 (1994) 79
13. Malats N., Bustos A., Nascimento C.M., Fernandez F., Rivas M., Puente D., et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6 (2005) 678
14. Smith N.D., Rubenstein J.N., Eggener S.E., and Kozlowski J.M. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 169 (2003) 1219
15. Schmitz-Drager B.J., Goebell P.J., Ebert T., and Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?. Eur Urol 38 (2000) 691
16. Masters J.R., Vani U.D., Grigor K.M., Griffiths G.O., Crook A., Parmar M.K., et al. Can p53 staining be used to identify patients with aggressive superficial bladder cancer?. J Pathol 200 (2003) 74
17. Gao J.P., Uchida T., Wang C., Jiang S.X., Matsumoto K., Satoh T., et al. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Int J Oncol 16 (2000) 469
18. Bernardini S., Adessi G.L., Billerey C., Chezy E., Carbillet J.P., and Bittard H. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol 162 (1999) 1496
19. Sarkis A.S., Dalbagni G., Cordon-Cardo C., Zhang Z.F., Sheinfeld J., Fair W.R., et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85 (1993) 53
20. Uchida T., Wada C., Ishida H., Wang C., Egawa S., Yokoyama E., et al. p53 mutations and prognosis in bladder tumors. J Urol 153 (1995) 1097